We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Weekly
    • FDAnews
  • Device News
    • Trending
    • Commercial Operations
    • FDA Enforcement Actions
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Weekly
    • FDAnews
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
    • Webinar Recordings
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
  • CenterWatch
  • About Us
    • The Company
    • FDAnews Editorial Board
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Ambco Warned Over CAPAs Following FDA, DPH Inspections

Ambco Warned Over CAPAs Following FDA, DPH Inspections

October 29, 2014

The FDA has warned Ambco Electronics after the devicemaker failed to correct deficiencies noted during a California Department of Public Health inspection and an earlier FDA inspection.

Ambco, which makes audiometers, received a violations notice from the health department on May 17, 2008, and an FDA Form 483 on Dec. 10 of that year, according to the Sept. 26 letter posted recently online. The company initiated two corrective and preventive actions to address the deficiencies, and a July 8-27, 2014, FDA inspection found the status of those CAPAs listed as completed.

But the Tustin, Calif., company lacked documentation of the corrections, and “our current inspection found many previous deficiencies were not corrected,” the letter says. Identified in the latest inspection were issues with receiving inspection procedures, component identification and traceability, acceptance activities, CAPA activities, trending and analysis of data sources, device history records and employee training.

Further, the company failed to properly implement its CAPA procedure, the FDA notes. The procedure requires investigations of devices reported or returned from the field as defective or malfunctioning, but Ambco hadn’t documented a review of potential trends or a trending analysis of customer experience reports, as required.

Ambco’s customer experience reports also failed to include details and data on the investigations and tests the company performed.

Vendor qualification also came under the microscope, as Ambco had neither implemented its qualification procedure nor defined and documented the specifications that component suppliers must meet.

“Your firm has not performed audits of custom device components, such as the keypad membrane and the firmware, and there is no ISO registration for those firms on file,” the warning letter says. The FDA will assess Ambco’s corrective actions in a follow-up inspection.

In addition to these issues, the investigator, from the FDA’s Los Angeles district office found that while Ambco routinely calibrates its devices, its standard operating procedure lacks specific instructions for calibration. The company also did not always complete a form required for these procedures.

The finished device acceptance testing and calibration procedure for one audiometer model failed to include specific instructions, as well as accuracy and precision limits, and it did not identify acceptable results, the letter says.

Meanwhile, Ambco’s device history records don’t include the complete acceptance records and primary identification label for each production unit, and the company could not provide appropriate personnel training records at the time of the inspection.

    Upcoming Events

    • 30Nov

      Medical Device Cybersecurity: Latest Regulatory Developments

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 07Dec

      Proactive Supplier Management Using Quality Agreements

    • 13Dec

      FDA Inspection Overhaul: How Things Have Changed in 2023

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • FDA, FTC and DOJ Enforcement of Medical Device Regulations

      FDA, FTC and DOJ Enforcement of Medical Device Regulations

    • Using Real-World Evidence in Drug and Device Submissions

      Using Real-World Evidence in Drug and Device Submissions

    Featured Stories

    • Lilly’s Claims of Mounjaro Trademark Infringement Get ITC Investigation

    • Positive Findings Generated by Element Science’s Jewel Wearable Cardiac Defibrillator

    • Biden Offers Drug Supply Chain Fixes, but Think Tank Says Government Isn’t Doing Enough

    • FDA Gives Green Light to Medtronic’s Symplicity Renal Denervation System

    The Revised ICH E8: A Guide to New Clinical Trial Requirements

    Learn More
    • Drug Products
      • Quality
      • Regulatory Affairs
      • GMPs
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Device Products
      • Quality
      • Regulatory Affairs
      • QSR
      • Inspections and Audits
      • Postmarket Safety
      • Submissions and Approvals
      • Research and Development
      • Commercial Operations
    • Clinical Products
      • Trial Design
      • Data Integrity
      • GCP
      • Inspections and Audits
      • Transparency
    • Privacy Policy
    • Do Not Sell or Share My Data
    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing